ATNM · XBRL financial data

Actinium Pharmaceuticals financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (ATNM's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue	—	1,144	1,030	81	—	90
Cost of revenue	—	900	—	—	—	—
Research and development	16,085	18,031	23,135	38,670	30,045	21,124
General and administrative	6,308	8,077	11,999	13,331	12,076	15,213
Total operating expenses	22,393	26,108	35,134	52,001	42,121	36,337
Operating income (loss)	(22,393)	(24,964)	(34,104)	(51,920)	(42,121)	(36,247)
Interest income	—	—	—	3,102	3,878	2,360
Net income (loss)	(22,215)	(24,774)	(33,017)	(48,818)	(38,243)	(33,887)
Earnings per share, basic USD per share	—	(1.20)	(1.37)	(1.83)	(1.27)	(1.09)
Earnings per share, diluted USD per share	—	(1.20)	(1.37)	(1.83)	(1.27)	(1.09)
Weighted average shares, basic thousands of shares	—	20,568	24,142	26,604	30,070	31,196
Weighted average shares, diluted thousands of shares	—	20,568	24,142	26,604	30,070	31,196

Fiscal years (ATNM's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	63,560	77,829	108,910	76,677	72,904	47,998
Prepaid and other current assets	1,317	1,478	1,636	1,586	1,602	1,383
Total current assets	64,925	79,749	110,942	78,263	74,506	49,381
Property and equipment, net	312	340	604	550	364	295
Right-of-use asset	579	241	2,341	2,289	1,685	1,754
Total assets	66,397	80,388	114,192	81,445	76,899	51,775
Total current liabilities	4,767	6,840	10,628	8,494	8,148	7,969
Lease liability, non-current	—	—	2,083	1,553	984	972
Total liabilities	5,078	6,843	47,711	45,066	44,141	43,941
Accumulated deficit	(230,974)	(255,748)	(288,765)	(337,583)	(375,826)	(409,713)
Total stockholders' equity	61,319	73,545	66,481	36,379	32,758	7,834
Total liabilities and equity	66,397	80,388	114,192	81,445	76,899	51,775
Common shares outstanding (cover page) thousands of shares	19,246	22,144	25,729	29,396	31,196	31,375

Fiscal years (ATNM's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(22,215)	(24,774)	(33,017)	(48,818)	(38,243)	(33,887)
Stock-based compensation	1,254	1,694	2,795	3,842	5,292	9,190
Depreciation and amortization	—	—	—	—	197	173
Net cash from operating activities	(21,617)	(20,866)	8,644	(47,335)	(33,072)	(24,580)
Purchases of property and equipment	253	133	366	153	11	104
Net cash from investing activities	(253)	(133)	(366)	(153)	(11)	(104)
Proceeds from issuing common stock	76,589	35,300	23,158	14,612	29,255	—
Proceeds from issuing equity	21,700	35,300	—	—	—	—
Net cash from financing activities	76,176	35,221	23,109	14,870	29,321	(217)
Net change in cash	54,306	14,222	31,387	—	(3,762)	(24,895)

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Actinium Pharmaceuticals	36,473	35,000	(5,179)*	31.4M	7.0 quarters	Q2 FY26 10-QJun 30, 2026
Fortress Biotech	196,576	18,718	(59,277)*	33.3M	3.3 quarters	Q2 FY26 10-QJun 30, 2026
Lite Strategy	5,706	not reported	(1,164)*	30.4M	4.9 quarters	Q4 FY26 10-KJun 30, 2026
Actuate Therapeutics	4,426	not reported	(4,405)*	24.0M	1.0 quarters	Q2 FY26 10-QJun 30, 2026
Acumen Pharmaceuticals	53,075	not reported	(26,653)*	72.3M	3.4 quarters	Q3 FY26 10-QSep 30, 2026
Opus Genetics	88,812	755	(11,950)*	83.2M	7.4 quarters	Q2 FY26 10-QJun 30, 2026
Precision Biosciences	81,698	0	(15,132)*	27.9M	6.1 quarters	Q3 FY26 10-QSep 30, 2026
CervoMed	22,463	0	(6,918)*	15.1M	3.6 quarters	Q2 FY26 10-QJun 30, 2026
Atara Biotherapeutics	3,221	630	(3,338)*	10.0M	3.0 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.